PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.92 EUR | +0.17% |
|
0.00% | -36.52% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.915
EUR
Average target price
6.85
EUR
Spread / Average Target
+134.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.52% | 18.88M | |
| -3.10% | 102B | |
| +1.75% | 96.07B | |
| -1.80% | 21.66B | |
| -17.77% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.01% | 13.79B | |
| +0.00% | 13.33B | |
| +18.94% | 10.94B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- European Equities Move Lower Friday, Set to End Week in Negative Territory
